Biologic therapy

Journal of Infusion Nursing

Volumn 35, Issue 5, 2012, Pages 301-313

  Eisenberg, Seth ^a  

^a Infusion Services   (United States)

Author keywords

Biotherapy; cytokines; hypersensitivity reactions; interferon; monoclonal antibodies; targeted therapy

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ALPHAN3 INTERFERON; BASILIXIMAB; BCG VACCINE; BELIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BRENTUXIMAB VEDOTIN; CERTOLIZUMAB PEGOL; CETUXIMAB; CYTOKINE; DACLIZUMAB; DENILEUKIN DIFTITOX; DENOSUMAB; ECULIZUMAB; ETANERCEPT; GAMMA1B INTERFERON; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERFERON BETA SERINE; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PEGINTERFERON ALPHA2A; PLERIXAFOR; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; ROMIPLOSTIM; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ANAPHYLAXIS; ANXIETY; BIOLOGICAL THERAPY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; CONFUSION; DEPRESSION; DERMATITIS; DIARRHEA; DRUG ACTIVITY; DRUG INDICATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENETIC ENGINEERING; HEADACHE; HUMAN; HYPERSENSITIVITY; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NURSING CARE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; URTICARIA; VOMITING;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CHEMOKINES; CYTOKINES; HUMANS; INTERFERONS; MYCOBACTERIUM BOVIS; NEOPLASMS;

EID: 84866378472     PISSN: 15331458     EISSN: 15390667     Source Type: Journal    
DOI: 10.1097/NAN.0b013e31826579aa     Document Type: Review

References (112)

1. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006; 61 (8): 912-920.
2. Wilkes GM, Barton-Burke M. 2010 Oncology Nursing Drug Handbook. Sudbury, MA: Jones & Bartlett; 2011.
3. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007; 11 (suppl 1): 37-42.
4. Coondoo A. Cytokines in dermatology: a basic overview. Indian J Dermatol. 2011; 56 (4): 368-374.
5. Parsons M. Cytokine storm in the pediatric oncology patient. J Pediatr Oncol Nurs. 2010; 27 (5): 253-258.
6. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 2008; 26 (6): 711-715.
7. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsycho-pharmacology. September 14, 2011:1-26.
8. Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum. 2006; 33 (3): 535-542.
9. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2011.
10. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008; 126 (2): 121-136.
11. Li M, Qin X, Xue X, et al. Safety evaluation and pharmacokinet-ics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity. Anticancer Drugs. 2010; 21 (3): 243-251.
12. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural Transm. July 9, 2011.
13. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011; 8 (2): 85-96.
14. Alferon N. Interferon alfa-N3 (Human Leukocyte Derived) [package insert]. Philadelphia, PA: Hemispherx-Biopharma. http://hemispherx.com/content/products/ product-brochure.htm. Accessed November 5, 2011.
15. Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011; 127 (3): 701-721. e701-e770.
16. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011; 41 (5): 1203-1217.
17. Proleukin (aldesleukin) [package insert]. Emeryville, CA: Bayer; 2011.
18. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011; 104 (7): 711-717.
19. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999; 21 (1): 75-87.
20. Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev. 2011; 10 (9): 563-568.
21. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharm. 2010; 160 (4): 810-820.
22. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006; 20 (4): 757-790.
23. Mozobil (plerixafor) [package insert]. Cambridge, MA: Genzyme; 2010.
24. T o LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011; 118 (17): 4530-4540.
25. TICE BCG [package insert]. Roseland, NJ: Organon; 2009.
26. Kaufmann SH. Novel tuberculosis vaccination strategies based on understanding the immune response. J Int Med. 2010; 267 (4): 337-353.
27. Ahirwar DK, Manchanda PK, Mittal RD, Bid HK. BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol. 2011; 137 (12): 1729-1738.
28. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006; 29 (1): 1-9.
29. Griggs J, Zinkewich-Peotti K. The state of the art: immunemediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer. 2009; 101 (11): 1807-1812.
30. Dillman RO. The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Curr Pharm Biotechnol. 2001; 2 (4): 293-300.
31. Beck A, Wurch T, Corvaia N. Therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol. 2008; 9 (6): 421-422.
32. Schroeder TJ, First MR, Mansour ME, et al. Antimurine antibody formation following OKT3 therapy. Transplantation. 1990; 49 (1): 48-51.
33. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001; 1 (2): 118-129.
34. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011; 11 (3): 262-268.
35. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9 (10): 767-774.
36. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010; 95 (1): 135-143.
37. Carney PH, Ollom CL. Infusion reactions triggered by monoclonal antibodies treating solid tumors. J Infus Nurs. 2008; 31 (2): 74-83.
38. Humira (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories; 2011.
39. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Ann Rev Immunol. 1994; 12: 433-455.
40. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305 (14): 1460-1468.
41. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010; 21 (1): 5-13.
42. Mylotarg (gemtuzumab ozogamicin injection) [package insert]. Philadelphia, PA: Wyeth; 2010.
43. Adcetris (brentuximab vedotin) [package insert]. Seattle, WA: SeattleGenetics, Inc.; 2011.
44. Zevalin (ibritumomab tiuxetan) [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2009.
45. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23 (9): 1137-1146.
46. Bexxar (tositumomab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
47. American Medical Association. Naming Biologics. http://www.ama-assn.org/ ama/pub/physician-resources/medical-science/unit-ed-states-adopted-names- council/naming-guidelines/naming-bio-logics/monoclonal-antibodies.page. Accessed November 6, 2011.
48. World Health Organization. General policies for monoclonal antibodies. http://apps.who.int/medicinedocs/documents/s19119en/s19119en.pdf. Accessed November 12, 2011.
49. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54 (9): 2793-2806.
50. Rituxan (rituximab) [package insert]. San Francisco, CA: Genentech; 2011.
51. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med. 2007; 146 (1): 25-33.
52. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010; 14 (2): E10-E21.
53. Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech; 2011.
54. Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther. 2003; 1 (1): 38-48.
55. Pegasys (peginterferon alfa-2a) [package insert]. South San Francisco, CA: Genentech; 2011.
56. Intron-A (interferon alfa-2b) [package insert]. Whitehouse Station, NJ: Schering; 2011.
57. Actimmune (interferon gamma 1b) [package insert]. Brisbane, CA: InterMune; 2009.
58. Betaseron (interferon beta-1b) [package insert]. Emeryville, CA: Chiron; 2003.
59. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13 (6): 725-732.
60. George TJ Jr, Laplant KD, Walden EO, et al. Managing cetuxi-mab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010; 8 (2): 72-77.
61. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuxi-mab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007; 25 (24): 3644-3648.
62. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizu-mab. Am J Health Syst Pharm. 2009; 66 (11): 999-1013.
63. Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
64. Wickham R. Osteoporosis related to disease or therapy in patients with cancer. Clin J Oncol Nurs. 2011; 15 (6): E90-E104.
65. Xgeva (denosumab) [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2010.
66. US Food and Drug Administration (FDA). Efalizumab (marketed as Raptiva) Postmarket Drug Safety Information for Patients and Providers. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm133337.htm. Accessed December 5, 2011.
67. Tysabri (natalizumab) [package insert]. South San Francisco, CA: Elan; 2011.
68. Arzerra (ofatumumab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
69. Erbitux (cetuximab) [package insert]. Branchberg, NJ: ImClone; 2009.
70. Vecitbix (panitumumab) [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2011.
71. Boucher J, Olson L, Piperdi B. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors. Clin J Oncol Nurs. 2011; 15 (5): 501-508.
72. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19 (8): 1079-1095.
73. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003; 124 (4): 917-924.
74. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008; 159 (3): 527-536.
75. Scherer K, Bircher AJ. Danger signs in drug hypersensitivity. Med Clin North Am. 2010; 94 (4): 681-689, xv-xx.
76. Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity: a consensus statement. Allergy. 2010; 65 (11): 1357-1366.
77. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010; 126 (3): 477-480.
78. Limsuwan T, Demoly P. Acute symptoms of drug hypersensitiv-ity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am. 2010; 94 (4): 691-710, x.
79. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. 2008; 63 (8): 1061-1070.
80. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006; 47 (4): 373-380.
81. Kanji S, Chant C. Allergic and hypersensitivity reactions in the intensive care unit. Crit Care Med. 2010; 38 (suppl 6): S162-S168.
82. Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Australia. 2006; 185 (5): 283-289.
83. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 2011; 60 (8): 1173-1180.
84. Younes A, Vose JM, Zelenetz AD, et al. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodg-kin's lymphoma. Br J Cancer. 2010; 103 (12): 1783-1787.
85. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29 (18): 2493-2498.
86. Amann M, D'Argouges S, Lorenczewski G, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother. 2009; 32 (5): 452-464.
87. Muller D, Kontermann RE. Bispecific antibodies for cancer immu-notherapy: current perspectives. BioDrugs. 2010; 24 (2): 89-98.
88. Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res. 2009; 15 (8): 2739-2746.
89. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011; 25 (1): 13-25.
90. Hadchity E, Aloy MT, Paulin C, et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol Ther. 2009; 17 (8): 1387-1394.
91. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum L T, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17 (12): 1685-1691.
92. van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin's lymphoma. Best Pract Res Clin Haematol. 2011; 24 (2): 231-256.
93. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010; 36 (6): 458-467.
94. ReoPro (abciximab) [package insert]. Leiden, NL: Centocor; 2005.
95. Amevive (alefacept) [package insert]. Deerfield, IL: Astellas; 2011.
96. Campath (alemtuzumab) [package insert]. Cambridge, MA: Genzyme; 2009.
97. Kineret (anakinra) [package insert]. Stockholm, Sweden: Sobi; 2011.
98. Simulect (basiliximab) [package insert]. East Hanover, NJ: Novartis; 2005.
99. Benlysta (belimumab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
100. Cimzia (certolizumab pegol) [package insert]. Smyrna, GA: UCB; 2010.
101. Zenapax (daclizumab) [package insert]. Nutley, NJ: Roche; 2005.
102. Ontak (denileukin diftitox) [package insert]. Ridgefield Park, NJ: Eisai; 2008.
103. Soliris (eculizumab) [package insert]. Cheshire, CT: Alexion Pharmaceuticals, Inc.; 2011.
104. Simponi (golimumab) [package insert]. Horsham, PA: Centocor; 2010.
105. Remicade (infliximab) [package insert]. Horsham, PA: Janssen; 2011.
106. Xolair (omalizumab) [package insert]. South San Francisco, CA: Genentech; 2007.
107. Neumega (oprelvekin) [package insert]. Philadelphia, PA: Wyeth; 2011.
108. Synagis (palivizumab) [package insert]. Gaithersburg, MD: Medimmune; 2011.
109. Nplate (romiplostim) [package insert]. Thousand Oaks, CA: Amgen; 2008.
110. Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech; 2011.
111. Herceptin (trastuzumab) [package insert]. South San Francisco, CA: Genentech; 2010.
112. Stelara (ustekinumab) [package insert]. Horsham, PA: Centocor; 2009.